Patient and Provider Perspectives on Genetic Risk Profiling
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Qualitative interview.
- Who it may be relevant to
- Registry conditions: Prostate Cancer. Basic parameters: 18 years — 100 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United Kingdom
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Exploring the Patient and Provider Perspectives on the Utility of Genetic Risk Profiling for Prostate Cancer in Routine Clinical Practice
Overview
A qualitative interview study exploring the patient and provider perspectives on the clinical utility of genetic risk profiling in routine clinical practice. The findings from the study may contribute towards future research and informing clinical practice.
Detailed description
Prostate cancer is the most prevalent cancer in men in the UK, however there are currently no formalised prostate cancer screening and risk management guidelines. Prostate cancer has a large heritable/genetic component and the combination of genetic alterations that a person inherits has a large influence on their risk. Genetic risk profiling can provide information on whether a person has a higher, average or lower genetic risk to develop prostate cancer. This can help to guide screening and management advice, with people at higher risk benefitting from increased surveillance and interventions, while sparing those at lower risk from unnecessary interventions. It can also provide guidance on potential treatments, prevention and reproductive risks and options. This can tailor and personalise healthcare for patients based on their risk, while also providing economic benefits to the healthcare system. Despite the benefits of genetic risk profiling, there are current concerns pertaining to the readiness for it's implementation into routine clinical practice given the lack of current risk management guidelines and uncertainty pertaining to actionability of results. Further research is essential to inform clinical practice.
This study will explore the perspectives of all stakeholders involved in the testing process, namely patients and healthcare providers who respectively receive and deliver genetic risk profiling results, to explore their viewpoints on the utility of genetic risk profiling in routine clinical practice. The research aims to explore current benefits, limitations, concerns and needs pertaining to genetic risk profiling which may contribute towards future research and clinical practice. Patients and providers who have received or delivered these results will be invited to participate in a once-off interview either at the Royal Marsden Hospital in Chelsea or Sutton or via video/telephone consultation. The research will be funded by the Royal Marsden Cancer Charity over 2 years.
Interventions
- Other Qualitative interview
Interview of participants to gain perspectives and experiences
Primary outcome measures
- Data pertaining to the experiences and perspectives of healthcare providers and patients regarding the clinical utility of genetic risk profiling in routine clinical practice, using a qualitative (interview) thematic analysis approach. [Time frame: January 2026 to August 2027]
Eligibility criteria
Inclusion criteria
- Individuals assigned male at birth who are aged 18 and over and who have capacity to consent
- Patients who have undergone genetic risk profiling for prostate cancer and have received their results
- Individuals from diverse backgrounds (age, ethnicity, risk status, etc)
- Healthcare providers who have delivered a genetic risk profiling result for prostate cancer
Exclusion criteria
- Individuals who lack capacity to consent
- Individuals deemed unsuitable to recruit based on their poor performance status or current medical condition
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
United Kingdom · 1 center
- The Royal Marsden Hospital (Sutton and Chelsea) — London
Identifiers
NCT: NCT07741929 · CCR6285